Jeffrey D Klausner1, Claire C Bristow2, Olusegun O Soge3, Akbar Shahkolahi4, Toni Waymer4, Robert K Bolan5, Susan S Philip6, Lenore E Asbel7, Stephanie N Taylor8, Leandro A Mena9, Deborah A Goldstein10, Jonathan A Powell11, Michael R Wierzbicki11, Sheldon R Morris2. 1. Departments of Medicine and Epidemiology, University of California, Los Angeles, Los Angeles, California, USA. 2. Department of Medicine, University of California, San Diego, La Jolla, California, USA. 3. Neisseria Reference Laboratory, University of Washington, Seattle, Washington, USA. 4. Social Scientific Systems, Silver Spring, Maryland, USA. 5. Los Angeles LGBT Center, Los Angeles, California, USA. 6. San Francisco Department of Public Health, San Francisco, California, USA. 7. Philadelphia Department of Public Health, Philadelphia, Pennsylvania, USA. 8. Louisiana State University Health Sciences Center, New Orleans, Louisiana, USA. 9. University of Mississippi Medical Center, Oxford, Mississippi, USA. 10. Whitman Walker Health, Washington, D.C., USA. 11. The Emmes Company, Rockville, Maryland, USA.
Abstract
BACKGROUND: Novel treatment strategies to slow the continued emergence and spread of antimicrobial resistance in Neisseria gonorrhoeae are urgently needed. A molecular assay that predicts in vitro ciprofloxacin susceptibility is now available but has not been systematically studied in human infections. METHODS: Using a genotypic polymerase chain reaction assay to determine the status of the N. gonorrhoeae gyrase subunit A serine 91 codon, we conducted a multisite prospective clinical study of the efficacy of a single oral dose of ciprofloxacin 500 mg in patients with culture-positive gonorrhea. Follow-up specimens for culture were collected to determine microbiological cure 5-10 days post-treatment. RESULTS: Of the 106 subjects possessing culture-positive infections with wild-type gyrA serine N. gonorrhoeae genotype, the efficacy of single-dose oral ciprofloxacin treatment in the per-protocol population was 100% (95% 1-sided confidence interval, 97.5-100%). CONCLUSIONS: Resistance-guided treatment of N. gonorrhoeae infections with single-dose oral ciprofloxacin was highly efficacious. The widespread introduction and scale-up of gyrA serine 91 genotyping in N. gonorrhoeae infections could have substantial medical and public health benefits in settings where the majority of gonococcal infections are ciprofloxacin susceptible. CLINICAL TRIALS REGISTRATION: NCT02961751.
BACKGROUND: Novel treatment strategies to slow the continued emergence and spread of antimicrobial resistance in Neisseria gonorrhoeae are urgently needed. A molecular assay that predicts in vitro ciprofloxacin susceptibility is now available but has not been systematically studied in human infections. METHODS: Using a genotypic polymerase chain reaction assay to determine the status of the N. gonorrhoeae gyrase subunit A serine 91 codon, we conducted a multisite prospective clinical study of the efficacy of a single oral dose of ciprofloxacin 500 mg in patients with culture-positive gonorrhea. Follow-up specimens for culture were collected to determine microbiological cure 5-10 days post-treatment. RESULTS: Of the 106 subjects possessing culture-positive infections with wild-type gyrA serine N. gonorrhoeae genotype, the efficacy of single-dose oral ciprofloxacin treatment in the per-protocol population was 100% (95% 1-sided confidence interval, 97.5-100%). CONCLUSIONS: Resistance-guided treatment of N. gonorrhoeae infections with single-dose oral ciprofloxacin was highly efficacious. The widespread introduction and scale-up of gyrA serine 91 genotyping in N. gonorrhoeae infections could have substantial medical and public health benefits in settings where the majority of gonococcal infections are ciprofloxacin susceptible. CLINICAL TRIALS REGISTRATION: NCT02961751.
Authors: Michael W Traeger; Vincent J Cornelisse; Jason Asselin; Brian Price; Norman J Roth; Jeff Willcox; Ban Kiem Tee; Christopher K Fairley; Christina C Chang; Jude Armishaw; Olga Vujovic; Matthew Penn; Pauline Cundill; George Forgan-Smith; John Gall; Claire Pickett; Luxi Lal; Anne Mak; Tim D Spelman; Long Nguyen; Dean A Murphy; Kathleen E Ryan; Carol El-Hayek; Michael West; Simon Ruth; Colin Batrouney; John T Lockwood; Jennifer F Hoy; Margaret E Hellard; Mark A Stoové; Edwina J Wright Journal: JAMA Date: 2019-04-09 Impact factor: 56.272
Authors: Vanessa G Allen; Leo Mitterni; Christine Seah; Anuradha Rebbapragada; Irene E Martin; Colin Lee; Heather Siebert; Lynn Towns; Roberto G Melano; Donald E Low Journal: JAMA Date: 2013-01-09 Impact factor: 56.272
Authors: Magnus Unemo; Monica M Lahra; Michelle Cole; Patricia Galarza; Francis Ndowa; Irene Martin; Jo-Anne R Dillon; Pilar Ramon-Pardo; Gail Bolan; Teodora Wi Journal: Sex Health Date: 2019-09 Impact factor: 2.706
Authors: Robert D Kirkcaldy; Edward W Hook; Olusegun O Soge; Carlos del Rio; Grace Kubin; Jonathan M Zenilman; John R Papp Journal: JAMA Date: 2015-11-03 Impact factor: 56.272
Authors: Ashleigh R Tuite; Thomas L Gift; Harrell W Chesson; Katherine Hsu; Joshua A Salomon; Yonatan H Grad Journal: J Infect Dis Date: 2017-11-27 Impact factor: 5.226
Authors: Jolein G E Laumen; Christophe Van Dijck; Sheeba S Manoharan-Basil; Saïd Abdellati; Irith De Baetselier; Vicky Cuylaerts; Tessa De Block; Dorien Van den Bossche; Basil B Xavier; Surbhi Malhotra-Kumar; Chris Kenyon Journal: Front Microbiol Date: 2021-11-25 Impact factor: 5.640